Here, we demonstrated that the clinical compound UDCA degraded both latent and activated TGF-β, as observed in various tumor cells and CD4+ T cells, indicating that UDCA is a pan-TGF-β inhibitor. This evidence concerns the gene TGFB1 and neoplasm.